Clinical trial · Interventional
Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)
Single-center, Open Trail of Phase 1 of M2ES With TC Regimen in Advanced NSCLC
NCT01099124CI-TRIAL-00009179completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate safety and tolerance of M2ES with TC regimen in advanced NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| M2ES | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- M2ES combined with chemotherapy
- interventionNames
- Drug: M2ES
Primary outcomes (1)
- measure
- Adverse events incidence,including severe adverse events incidence
- timeFrame
- one year
Secondary outcomes (1)
- measure
- Tumor response rate and disease controlled rate
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18-70 years old; 2. Patients with Ⅲ/Ⅳ NSCLC confirmed by histopathology or cytology who ware naive or previous chemotherapy without TC regimen; 3. No contraindication for chemotherapy; 4. ECOG performance scale 0-2; 5. No history of anti-angiogenesis therapy; 6. Patients are voluntary to participate and sigh the informed contents. Exclusion Criteria: 1. Concurrent use of other anti-cancer agents; 2. Allergic history to M2ES and biological agents; 3. Pregnant or breast-feeding women; 4. With other malignancy; 5. With severe cardiopulmonary disease; 6. Uncontrolled brain metastasis patients; 7. Other conditions that are regarded for exclusion by the trialists.
References
Publications (0)
Data not yet available
No reference posted for this study.